Related Experiment Video
Updated: Aug 6, 2026
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
New treatment approaches in metastatic renal cell carcinoma
Andrea Mancuso1, Cora N Sternberg
1Department of Medical Oncology, San Camillo Hospital, Rome, Italy.
Purpose Of Review:
Recent developments in the understanding of the molecular biology of renal cell carcinoma have led to the development of several biologic agents with different mechanisms of action. In 2005, promising results have been observed especially in second-line therapy following cytokine failures and in 2006 more mature data with regard to time to progression and overall survival should be available. This review, analyzing basic translational research principles, will summarize the available evidence with a glimpse of the future therapeutic approaches in renal cell carcinoma.
Recent Findings:
Vascular endothelial growth factor- and platelet-derived growth factor receptor-inhibiting drugs (SU11248, Bay 43-9006, Bevacizumab, AG-013736, etc.) report time to progression ranging between 4 and 9 months and variable benefits in overall survival. Confirmatory studies are ongoing regarding other novel treatments (CCI-779, Infliximab, PTK-787).
Summary:
In renal cell carcinoma, there is a strong rationale for targeting multiple pathways and particularly angiogenesis. Vascular endothelial growth factor- and platelet-derived growth factor receptor-inhibiting drugs have been rapidly approved in the second-line setting and will soon be used as first-line therapy. In the next years, translational/clinical research will provide evidence for combination strategies to improve upon the results of the biologic agents and hopefully offer more hope to patients with renal cell carcinoma.
Insights
New biologic agents targeting angiogenesis show promise in treating advanced renal cell carcinoma, offering improved outcomes in second-line therapy. Future research focuses on combination strategies for enhanced patient hope.
Area of Science:
- Oncology
- Molecular Biology
- Translational Research
Background:
- Renal cell carcinoma (RCC) understanding has advanced, leading to novel biologic agents.
- Cytokine therapy failures in RCC created a need for alternative treatments.
- Translational research principles guide the development of new RCC therapies.
Purpose of the Study:
- To review current evidence on biologic agents for renal cell carcinoma.
- To analyze the molecular biology underpinning RCC treatment.
- To provide a future outlook on therapeutic approaches for RCC.
Main Methods:
- Review of translational research principles.
- Analysis of available clinical trial data for biologic agents.
- Synthesis of evidence regarding angiogenesis inhibitors in RCC.
Main Results:
- Vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGFR) inhibitors demonstrate significant time to progression (4-9 months) in RCC.
- These agents show variable benefits in overall survival for renal cell carcinoma patients.
- Ongoing studies are evaluating other novel treatments like CCI-779 and Infliximab.
Conclusions:
- Targeting multiple pathways, especially angiogenesis, is crucial for renal cell carcinoma treatment.
- VEGF/PDGFR inhibitors are rapidly adopted for second-line RCC therapy and may become first-line.
- Combination strategies are the future for improving RCC outcomes and patient prognosis.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
02:56Treatment Resistent Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...